JN Nova Pharma is a Canadian bio-tech company working with technology from National Research Council of Canada. Our lead product is a promising biological, anti- COVID19 therapeutic agent, with a key feature of long-duration of angiotensin-converting enzyme 2 (ACE2) replacement function. The drug mechanism is also specifically designed to treat acute kidney injury (AKI) and prevent chronic kidney disease (CKD), a major unmet need in the Arab World, where three key risk factors– diabetes, hypertension and obesity–are more prevalent than anywhere else in the world. Our candidate is in early-stage Good Manufacturing Practice (GMP) bio-manufacturing and in regulatory submission for clinical trial entry for 2022.

JN Nova Pharma Inc. Logo



Event details

Date: January 24 - 27, 2022

Event contact

Eyad Qudsi
Area Director
Middle East and Africa


18 in total